Should I undergo germline genetic testing for colorectal cancer?

Germline Genetic Testing for Colorectal Cancer

You should undergo germline genetic testing for colorectal cancer if you have been diagnosed with colorectal cancer at any age, or if you have a family history suggestive of hereditary colorectal cancer syndromes. The evidence strongly supports universal tumor testing for all colorectal cancer patients, followed by germline testing when indicated, as this approach identifies hereditary cancer syndromes that directly impact treatment decisions, surveillance strategies, and family member screening—ultimately reducing cancer mortality. 1

Who Should Undergo Germline Testing

If You Have Been Diagnosed with Colorectal Cancer

All patients with newly diagnosed colorectal cancer should have their tumor tested first using immunohistochemistry (IHC) for mismatch repair (MMR) proteins (MLH1, MSH2, MSH6, PMS2) or microsatellite instability (MSI) testing. 1 This initial tumor screening identifies which patients need germline genetic testing.

Proceed to germline genetic testing if:

• Your tumor shows loss of MSH2, MSH6, or PMS2 proteins—germline testing should be performed immediately for the corresponding genes 1
• Your tumor shows loss of MLH1/PMS2 AND testing reveals no BRAF V600E mutation or MLH1 promoter methylation (ruling out sporadic cancer) 1
• You were diagnosed under age 50 years, regardless of tumor testing results 1
• You have multiple colorectal cancers (synchronous or metachronous) at any age 1
• You have 10 or more adenomatous polyps—testing for APC and MUTYH genes is indicated 1

If You Have NOT Been Diagnosed with Cancer But Have Family History

You should pursue germline genetic testing if:

• A family member has a known pathogenic variant in Lynch syndrome genes (MLH1, MSH2, MSH6, PMS2, EPCAM) or other hereditary colorectal cancer genes 1
• You have a first-degree relative with colorectal or endometrial cancer diagnosed before age 50 1
• You have two or more first- or second-degree relatives with Lynch syndrome-related cancers at any age 1
• No living affected family member is available for testing, but family history strongly suggests hereditary syndrome 1

What Type of Testing to Request

Request multigene panel testing rather than single-gene testing when germline testing is indicated, as multiple genes may be relevant to your personal and family history. 1, 2

The minimal panel should include:

• Lynch syndrome genes: MLH1, MSH2, MSH6, PMS2, EPCAM (these account for 3-10% of all colorectal cancers and carry 10-48% lifetime colorectal cancer risk depending on the specific gene) 1
• Polyposis genes: APC (for familial adenomatous polyposis with 100% lifetime risk), MUTYH (for MUTYH-associated polyposis with 63% lifetime risk by age 60) 1
• Additional moderate-risk genes: CHEK2, BMPR1A, SMAD4, STK11, POLD1, POLE 1, 3

Recent research demonstrates that 7.8-15.5% of colorectal cancer patients carry pathogenic germline variants, with approximately one-third of these variants found in genes beyond Lynch syndrome that would be missed by narrow testing panels. 3, 4 Broader panels are particularly valuable for patients over age 40 years to clarify inheritance risks for family members. 3

Why This Testing Matters for Your Health

Direct Impact on Your Cancer Treatment

• Immunotherapy eligibility: Lynch syndrome tumors with mismatch repair deficiency respond dramatically to immune checkpoint inhibitors, fundamentally changing treatment options for metastatic disease 1
• Surgical decision-making: Knowing you carry a pathogenic variant influences whether to perform more extensive initial surgery (e.g., total colectomy vs. segmental resection) given high risk of metachronous cancers 1

Cancer Prevention Through Surveillance

If you carry a Lynch syndrome pathogenic variant:

• Colonoscopy every 1-2 years starting at age 20-25 years (or 10 years before youngest family diagnosis) prevents colorectal cancer through early polyp detection 1
• Annual gynecological surveillance for endometrial cancer (lifetime risk 34-60% depending on gene) 1
• Consideration of risk-reducing gynecological surgery after age 35 and completion of childbearing 1

If you carry FAP (APC gene) pathogenic variant:

• Colonoscopy every 1-3 years starting at age 12-14 years 1
• Risk-reducing colectomy when polyp burden becomes unmanageable or high-grade dysplasia develops 1

Family Member Protection

Cascade testing of your relatives can be lifesaving. When a pathogenic variant is identified in you, first-degree relatives have a 50% chance of carrying the same variant. 1 Testing them enables early surveillance that reduces their colorectal cancer mortality. However, uptake of family cascade testing remains disappointingly low at only 16%, representing a critical gap in preventive care. 4, 5

Common Pitfalls to Avoid

Do not wait for "strong enough" family history. Research shows that 9.4% of patients with colorectal cancer have clinically actionable genetic findings that would not have been detected using traditional guideline criteria based on age or family history alone. 4 Universal testing identifies these cases.

Do not assume older age at diagnosis excludes hereditary cancer. While pathogenic variants are more common in younger patients, they occur across all age groups, and the implications for family members remain critical regardless of the proband's age. 3, 4

Do not skip tumor testing and go straight to germline testing (unless family history is extremely compelling). The tumor testing algorithm efficiently triages which patients need germline testing and which genes to prioritize, avoiding unnecessary germline testing costs. 1

Ensure proper genetic counseling is part of the process, particularly for multigene panel interpretation, as variants of uncertain significance and incidental findings require expert interpretation. 1, 5

Implementation Barriers and Solutions

Current barriers to universal germline testing include limited genetics knowledge among non-genetics providers, time-consuming consent processes, and insurance coverage concerns. 5 However, 73% of hereditary GI cancer experts support universal germline testing for colorectal cancer patients, recognizing that alternative service delivery models using non-genetics providers can address logistical challenges. 5

The cost-effectiveness of universal germline testing is favorable, with studies showing that most patients (95%) with identified pathogenic variants benefit from enhanced surveillance and tailored treatment. 3